Finoriq research workspace
Xenon Pharmaceuticals Inc. (XENE) Institutional Holdings & 13F Ownership
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the. Review XENE institutional holders, 13F ownership, and position changes on Finoriq.
Company Snapshot
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
- Company
- Xenon Pharmaceuticals Inc. (XENE)
- Ticker
- XENE
- Market Cap
- $6.4B
- Latest Price
- $66.56
- Industry
- Biotech & Pharma
Xenon Pharmaceuticals Inc. (XENE) Top Institutional Holders
Top current 13F holders indexed for Xenon Pharmaceuticals Inc. (XENE). Latest period 2026-03-31.
| Rank | Investor | Value | Portfolio | Filing |
|---|---|---|---|---|
| 1 | Stanley DruckenmillerCIK 0001536411 | $13.9M | 0.41% | Filing2026-05-15 |
| 2 | Ron BaronCIK 0001017918 | $1.5M | 0.0% | Filing2026-05-15 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.